UNLU_IRG2010 · DOT/MRI Dual-Modality Cancer Imaging Using a Bifunctional Contrast Agent
FP7 — People (Marie Curie Actions)
- Duration
- 2010-09-01 → 2014-08-31
- EU contribution
- €100,000
- Participants
- 1
- Scheme
- MC-IRG
Lines connect the coordinator with its partners.
Results in brief
DOT/MRI Dual-Modality Cancer Imaging Using a Bifunctional Contrast Agent
There were two goals of the project. The first was the technology development. The technology development part consisted of two sub goals: a) the development of a novel multi-modality dynamic imaging system and b) the development of polymer based bi-functional and mono- functional optical agents. It is important to note that bi-functional contrast agents are ideal for multimodal imaging systems. Each imaging modality can independently track the dynamics of the same contrast agent. This enables various applications such as in vivo validation studies. Both goals were achieved successfully. During the project, one large and one medium size polymer based bi-functional contrast agent were produced for a combined diffuse optical tomography/magnetic resonance imaging (DOT/MRI) system that was located in Tu and Yuen Center for Functional Onco-Imaging, University of California, Irvine. The system was able to measure the enhancement kinetics of the mono-functional optical contrast agents or bi-functional optical/MR contrast agents. Besides, the detection of the endogenous contrast difference between normal and cancerous tissue due to differences in hemoglobin content and scattering properties was possible. The bi-functional contrast agents were tested in small animal tumor models. All animal procedures were approved by the Institutional Animal Care and Use Committee at University of California, Irvine. Fisher rats with 180 gram average weight were used in the studies. The rat was placed inside the DOT/MRI system. The polymer based bi-functional contrast agents produced by GE Global Research, NY were injected. Data acquisition was done simultaneously by DOT and MRI systems. Results showed that the enhancement kinetics measured by DOT and MRI were similar. In particular, wash in pattern and the location of the peak enhancement in time detected by both modalities overlapped. However, in general, MRI kinetic curve showed a faster wash-out pattern whereas the optical one was slower.
Data: CORDIS, © European Union
Project objective
New exogenous molecular probes have been used in the optical imaging field. We have already developed a multi-frequency & multispectral optical tomography animal imaging system. The system has been integrated to a magnetic resonance imaging (MRI) system. In this project, we will expand our hybrid system to measure dynamic information from exogenous probes. This system would measure the enhancement kinetics of the bi-functional optical/MR or mono-functional optical contrast agents and the endogenous contrast due to hemoglobin contents and scattering properties. There are two parts of the proposal. In the first part, we will development a novel multi-modality dynamic imaging system. Inthe second part, we will develop polymer based bi-functional and mono-functional optical agents. Such a hybrid system would facilitate the development of new contrast agents for biomedical imaging and that the development of polymer based molecular agents will provide a potential new molecular platform for these new contrast agents. At the end of this project, we will be able to test our hypothesis that “the parameters obtained bymacromolecular optical agent together with total hemoglobin, oxygen saturation and tissue scattering parameters can achieve a higher specificity in differentiating between ENU induced malignant and benign tumors compared to MRI parameters measured by low molecular weight extracellular MRI agents”.
Original text from CORDIS.
Participants
- BOGAZICI UNIVERSITESI · IstanbulCoordinatorTürkiye
Links
Data: CORDIS, © European Union